GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
TrustPilot
法蒂玛 A.
3天前
安妮塔· G.
2 个月前
伊姆兰 F.
2 周前
Ayesha M.
5天前
